## Michael R Shurin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5540111/publications.pdf

Version: 2024-02-01

44069 62596 7,461 160 48 citations h-index papers

80 g-index 167 167 167 10182 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Blocking IL- $1\hat{l}^2$ reverses the immunosuppression in mouse breast cancer and synergizes with antiâ $\in$ "PD-1 for tumor abrogation. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 1361-1369.	7.1	302
2	Dendritic Cells in the Cancer Microenvironment. Journal of Cancer, 2013, 4, 36-44.	2.5	289
3	Current understanding of interactions between nanoparticles and the immune system. Toxicology and Applied Pharmacology, 2016, 299, 78-89.	2.8	236
4	Chemotherapeutic Agents in Noncytotoxic Concentrations Increase Antigen Presentation by Dendritic Cells via an IL-12-Dependent Mechanism. Journal of Immunology, 2009, 183, 137-144.	0.8	221
5	FLT3 Ligand Induces the Generation of Functionally Active Dendritic Cells in Mice. Cellular Immunology, 1997, 179, 174-184.	3.0	199
6	Loss of New Chemokine CXCL14 in Tumor Tissue Is Associated with Low Infiltration by Dendritic Cells (DC), while Restoration of Human CXCL14 Expression in Tumor Cells Causes Attraction of DC Both In Vitro and In Vivo. Journal of Immunology, 2005, 174, 5490-5498.	0.8	198
7	Antitumor Effect of Paclitaxel Is Mediated by Inhibition of Myeloid-Derived Suppressor Cells and Chronic Inflammation in the Spontaneous Melanoma Model. Journal of Immunology, 2013, 190, 2464-2471.	0.8	195
8	Cyanidin-3-rutinoside, a Natural Polyphenol Antioxidant, Selectively Kills Leukemic Cells by Induction of Oxidative Stress. Journal of Biological Chemistry, 2007, 282, 13468-13476.	3.4	185
9	Th1/Th2 balance in cancer, transplantation and pregnancy. Seminars in Immunopathology, 1999, 21, 339-359.	4.0	180
10	Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies?. Cancer and Metastasis Reviews, 2006, 25, 333-356.	5.9	163
11	New flow cytometric assays for monitoring cell-mediated cytotoxicity. Expert Review of Vaccines, 2010, 9, 601-616.	4.4	142
12	Rapid Detection of SARS-CoV-2 Antigens Using High-Purity Semiconducting Single-Walled Carbon Nanotube-Based Field-Effect Transistors. ACS Applied Materials & Samp; Interfaces, 2021, 13, 10321-10327.	8.0	139
13	Chemomodulation of human dendritic cell function by antineoplastic agents in low noncytotoxic concentrations. Journal of Translational Medicine, 2009, 7, 58.	4.4	128
14	Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells (i) in vitro (i) in a TLR4-independent manner. Journal of Immunotoxicology, 2012, 9, 292-300.	1.7	124
15	Low-Dose Paclitaxel Prior to Intratumoral Dendritic Cell Vaccine Modulates Intratumoral Cytokine Network and Lung Cancer Growth. Clinical Cancer Research, 2007, 13, 5455-5462.	7.0	120
16	Direct Effects of Carbon Nanotubes on Dendritic Cells Induce Immune Suppression Upon Pulmonary Exposure. ACS Nano, 2011, 5, 5755-5762.	14.6	116
17	Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects. Microbiology Spectrum, 2021, 9, e0034121.	3.0	114
18	Tumor associated regulatory dendritic cells. Seminars in Cancer Biology, 2012, 22, 298-306.	9.6	112

#	Article	IF	CITATIONS
19	Dendritic cells presenting tumor antigen. Cancer Immunology, Immunotherapy, 1996, 43, 158-164.	4.2	110
20	Tumor-derived factors modulating dendritic cell function. Cancer Immunology, Immunotherapy, 2016, 65, 821-833.	4.2	107
21	Myeloid regulatory cells in tumor spreading and metastasis. Immunobiology, 2015, 220, 236-242.	1.9	105
22	Bone marrow-derived dendritic cells pulsed with a tumor-specific peptide elicit effective anti-tumor immunity against intracranial neoplasms., 1998, 78, 196-201.		95
23	Tumor's other immune targets: dendritic cells. Journal of Leukocyte Biology, 1999, 66, 336-344.	3.3	92
24	Dynamic alteration of soluble serum biomarkers in healthy aging. Cytokine, 2007, 39, 123-129.	3.2	91
25	Immunosuppressive Mechanisms of Regulatory Dendritic Cells in Cancer. Cancer Microenvironment, 2013, 6, 159-167.	3.1	90
26	Enzymatic oxidative biodegradation of nanoparticles: Mechanisms, significance and applications. Toxicology and Applied Pharmacology, 2016, 299, 58-69.	2.8	89
27	Antigen-Processing Machinery in Human Dendritic Cells: Up-Regulation by Maturation and Down-Regulation by Tumor Cells. Journal of Immunology, 2004, 173, 1526-1534.	0.8	86
28	EFFECTS OF VITAMIN D (CALCITRIOL) ON TRANSITIONAL CELL CARCINOMA OF THE BLADDER IN VITRO AND IN VIVO. Journal of Urology, 2001, 165, 253-258.	0.4	85
29	Transduction of Dendritic Cells with Bcl-xLIncreases Their Resistance to Prostate Cancer-Induced Apoptosis and Antitumor Effect in Mice. Journal of Immunology, 2000, 165, 1956-1964.	0.8	78
30	Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells. Cellular Oncology (Dordrecht), 2011, 34, 97-106.	4.4	78
31	Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. International Journal of Cancer, 2002, 101, 61-68.	5.1	77
32	Graphene Oxide, But Not Fullerenes, Targets Immunoproteasomes and Suppresses Antigen Presentation by Dendritic Cells. Small, 2013, 9, 1686-1690.	10.0	75
33	ChemolmmunoModulation: Immune Regulation by the Antineoplastic Chemotherapeutic Agents. Current Medicinal Chemistry, 2012, 19, 1792-1803.	2.4	74
34	Restoration by IL-15 of MHC Class I Antigen-Processing Machinery in Human Dendritic Cells Inhibited by Tumor-Derived Gangliosides. Journal of Immunology, 2005, 175, 3045-3052.	0.8	71
35	Aging and the dendritic cell system: Implications for cancer. Critical Reviews in Oncology/Hematology, 2007, 64, 90-105.	4.4	69
36	C-reactive protein and lung diseases. International Journal of Biochemistry and Cell Biology, 2014, 53, 77-88.	2.8	69

#	Article	IF	CITATIONS
37	Human prostate cancer regulates generation and maturation of monocyte-derived dendritic cells. Prostate, 2001, 46, 68-75.	2.3	67
38	Small Rho GTPases Regulate Antigen Presentation in Dendritic Cells. Journal of Immunology, 2005, 174, 3394-3400.	0.8	67
39	Human Small Cell Lung Carcinoma and Carcinoid Tumor Regulate Dendritic Cell Maturation and Function. Modern Pathology, 2001, 14, 40-45.	5.5	66
40	Carbon Nanotubes Enhance Metastatic Growth of Lung Carcinoma via Upâ€Regulation of Myeloidâ€Derived Suppressor Cells. Small, 2013, 9, 1691-1695.	10.0	61
41	Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood, 2004, 104, 2107-2115.	1.4	57
42	Clinical evaluation of systemic and local immune responses in cancer: time for integration. Cancer Immunology, Immunotherapy, 2014, 63, 45-57.	4.2	56
43	Regulatory dendritic cells: New targets for cancer immunotherapy. Cancer Biology and Therapy, 2011, 11, 988-992.	3.4	54
44	Schwann Cells Augment Cell Spreading and Metastasis of Lung Cancer. Cancer Research, 2018, 78, 5927-5939.	0.9	54
45	Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice. Journal of Immunotoxicology, 2012, 9, 275-281.	1.7	52
46	ELISPOT Assay for Monitoring Cytotoxic T Lymphocytes (CTL) Activity in Cancer Vaccine Clinical Trials. Cells, 2012, 1, 111-126.	4.1	52
47	Graphene Oxide Attenuates Th2-Type Immune Responses, but Augments Airway Remodeling and Hyperresponsiveness in a Murine Model of Asthma. ACS Nano, 2014, 8, 5585-5599.	14.6	51
48	Regulatory dendritic cells in the tumor immunoenvironment. Cancer Immunology, Immunotherapy, 2012, 61, 223-230.	4.2	50
49	Biodiesel versus diesel exposure: Enhanced pulmonary inflammation, oxidative stress, and differential morphological changes in the mouse lung. Toxicology and Applied Pharmacology, 2013, 272, 373-383.	2.8	50
50	MDSC and $TGF\hat{l}^2$ Are Required for Facilitation of Tumor Growth in the Lungs of Mice Exposed to Carbon Nanotubes. Cancer Research, 2015, 75, 1615-1623.	0.9	50
51	Lung cancer-derived bombesin-like peptides down-regulate the generation and function of human dendritic cells. Journal of Neuroimmunology, 2003, 145, 55-67.	2.3	49
52	Dopamine receptors in human lymphocytes: Radioligand binding and quantitative RT-PCR assays. Journal of Neuroscience Methods, 2008, 174, 272-280.	2.5	49
53	Targeting Myeloid-Derived Suppressor Cells in Cancer. Advances in Experimental Medicine and Biology, 2017, 1036, 105-128.	1.6	49
54	Epigenetic Mechanisms of Promigratory Chemokine CXCL14 Regulation in Human Prostate Cancer Cells. Cancer Research, 2010, 70, 4394-4401.	0.9	48

#	Article	IF	CITATIONS
55	Melanoma-Induced Reprogramming of Schwann Cell Signaling Aids Tumor Growth. Cancer Research, 2019, 79, 2736-2747.	0.9	48
56	CD154 inhibits tumor-induced apoptosis in dendritic cells and tumor growth. European Journal of Immunology, 1999, 29, 2148-2155.	2.9	47
57	Local administration of ILâ€12–transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice. Journal of Experimental Therapeutics and Oncology, 2002, 2, 337-349.	0.5	47
58	Inhibition of Dendropoiesis by Tumor Derived and Purified Prostate Specific Antigen. Journal of Urology, 2003, 170, 2026-2030.	0.4	47
59	Origin and pharmacological modulation of tumorâ€associated regulatory dendritic cells. International Journal of Cancer, 2014, 134, 2633-2645.	5.1	47
60	Fibrous nanocellulose, crystalline nanocellulose, carbon nanotubes, and crocidolite asbestos elicit disparate immune responses upon pharyngeal aspiration in mice. Journal of Immunotoxicology, 2018, 15, 12-23.	1.7	45
61	Mechanisms of dendritic cell-induced T cell proliferation in the primary MLR assay. Immunology Letters, 2001, 78, 75-82.	2.5	41
62	Identification of delta- and mu-type opioid receptors on human and murine dendritic cells. Journal of Neuroimmunology, 2001, 117, 68-77.	2.3	40
63	Schwann cells: a new player in the tumor microenvironment. Cancer Immunology, Immunotherapy, 2017, 66, 959-968.	4.2	39
64	The Neuroimmune Axis in the Tumor Microenvironment. Journal of Immunology, 2020, 204, 280-285.	0.8	39
65	Osteopontin controls immunosuppression in the tumor microenvironment. Journal of Clinical Investigation, 2018, 128, 5209-5212.	8.2	38
66	H1(0) histone and differentiation of dendritic cells. A molecular target for tumor-derived factors. Journal of Leukocyte Biology, 2002, 72, 285-96.	3.3	38
67	Dual role of immunomodulation by anticancer chemotherapy. Nature Medicine, 2013, 19, 20-22.	30.7	37
68	Schwann cells shape the neuro-immune environs and control cancer progression. Cancer Immunology, Immunotherapy, 2019, 68, 1819-1829.	4.2	37
69	Low-dose Chemotherapeutic Agents Regulate Small Rho GTPase Activity in Dendritic Cells. Journal of Immunotherapy, 2008, 31, 491-499.	2.4	36
70	Targeting myeloid regulatory cells in cancer by chemotherapeutic agents. Immunologic Research, 2011, 50, 276-285.	2.9	36
71	Nano-Gold Corking and Enzymatic Uncorking of Carbon Nanotube Cups. Journal of the American Chemical Society, 2015, 137, 675-684.	13.7	36
72	Cancer as an immune-mediated disease. ImmunoTargets and Therapy, 2012, 1, 1.	5.8	35

#	Article	IF	Citations
73	Cross-talk between HIF and PD-1/PD-L1 pathways in carcinogenesis and therapy. Journal of Clinical Investigation, 2022, 132, .	8.2	33
74	Immunomodulation by Schwann cells in disease. Cancer Immunology, Immunotherapy, 2020, 69, 245-253.	4.2	32
75	Dual Acute Proinflammatory and Antifibrotic Pulmonary Effects of Short Palate, Lung, and Nasal Epithelium Clone–1 after Exposure to Carbon Nanotubes. American Journal of Respiratory Cell and Molecular Biology, 2013, 49, 759-767.	2.9	31
76	Small Rho GTPases Mediate Tumor-Induced Inhibition of Endocytic Activity of Dendritic Cells. Journal of Immunology, 2007, 178, 7787-7793.	0.8	30
77	Optimizing dendritic cell-based immunotherapy for cancer. Expert Review of Vaccines, 2007, 6, 333-345.	4.4	29
78	Impact of the Sensory Neurons on Melanoma Growth In Vivo. PLoS ONE, 2016, 11, e0156095.	2.5	29
79	Human Prostate Cancer Blocks the Generation of Dendritic Cells from CD34+ Hematopoietic Progenitors. European Urology, 2001, 39, 37-40.	1.9	27
80	Variable Performance in 6 Commercial SARS-CoV-2 Antibody Assays May Affect Convalescent Plasma and Seroprevalence Screening. American Journal of Clinical Pathology, 2021, 155, 343-353.	0.7	27
81	Antibody Responses After mRNA-Based COVID-19 Vaccination in Residential Older Adults: Implications for Reopening. Journal of the American Medical Directors Association, 2021, 22, 1593-1598.	2.5	25
82	The generation of human dendritic and NK cells from hemopoietic progenitors induced by interleukin-15. Journal of Leukocyte Biology, 1999, 66, 659-666.	3.3	24
83	Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBLin vivo following intratumoral administration of viral vectors or transduced dendritic cells. Journal of Gene Medicine, 2006, 8, 129-137.	2.8	24
84	Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunology, Immunotherapy, 2012, 61, 239-247.	4.2	24
85	Interferon regulatory factor 8 mediates tumor-induced inhibition of antigen processing and presentation by dendritic cells. Cancer Immunology, Immunotherapy, 2009, 58, 567-574.	4.2	22
86	Increased function and survival of IL-15-transduced human dendritic cells are mediated by up-regulation of IL-15Ralpha and Bcl-2. Journal of Leukocyte Biology, 2002, 72, 1037-45.	3.3	22
87	Immunological Mechanisms of Low and Ultra-Low Dose Cancer Chemotherapy. Cancer Microenvironment, 2015, 8, 57-64.	3.1	21
88	Murine prostate cancer inhibits both in vivo and in vitro generation of dendritic cells from bone marrow precursors. Prostate, 2004, 59, 203-213.	2.3	20
89	Comparative analysis of dendritic cells transduced with different anti-apoptotic molecules: sensitivity to tumor-induced apoptosis. Journal of Gene Medicine, 2004, 6, 537-544.	2.8	20
90	The Role of TLR4 in the Paclitaxel Effects on Neuronal Growth In Vitro. PLoS ONE, 2013, 8, e56886.	2.5	20

#	Article	IF	CITATIONS
91	BAFF and APRIL from Activin A–Treated Dendritic Cells Upregulate the Antitumor Efficacy of Dendritic Cells <i>In Vivo</i> . Cancer Research, 2016, 76, 4959-4969.	0.9	20
92	Nanoelectronic Discrimination of Nonmalignant and Malignant Cells Using Nanotube Field-Effect Transistors. ACS Sensors, 2017, 2, 1128-1132.	7.8	20
93	Targeting myeloid regulators by paclitaxel-loaded enzymatically degradable nanocups. Nanoscale, 2018, 10, 17990-18000.	5.6	20
94	Differential Regulation of Epidermal and Dermal Dendritic Cells by IL-12 and Flt3 Ligand. Journal of Investigative Dermatology, 1999, 113, 1028-1032.	0.7	19
95	Genetically modified dendritic cells in cancer immunotherapy: a better tomorrow?. Expert Opinion on Biological Therapy, 2010, 10, 1539-1553.	3.1	19
96	Mediation of the single-walled carbon nanotubes induced pulmonary fibrogenic response by osteopontin and TGF- $\hat{l}^21$ . Experimental Lung Research, 2017, 43, 311-326.	1.2	19
97	Effect of a conditioned aversive stimulus on the immune response in three strains of rats. Psychoneuroendocrinology, 1995, 20, 837-849.	2.7	18
98	Abnormalities in the male reproductive system after exposure to diesel and biodiesel blend. Environmental and Molecular Mutagenesis, 2015, 56, 265-276.	2.2	18
99	Inhibition of Dendritic Cell Generation and Function by Serum from Prostate Cancer Patients: Correlation with Serum-Free PSA. Advances in Experimental Medicine and Biology, 2007, 601, 173-182.	1.6	18
100	SARS-CoV-2 Serologic Immune Response in Exogenously Immunosuppressed Patients. journal of applied laboratory medicine, The, 2021, 6, 486-490.	1.3	17
101	Payload drug vs. nanocarrier biodegradation by myeloperoxidase- and peroxynitrite-mediated oxidations: pharmacokinetic implications. Nanoscale, 2015, 7, 8689-8694.	5.6	15
102	Dysregulated NF-κB–Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. Cancer Immunology Research, 2020, 8, 1554-1567.	3.4	15
103	Suppression of lymphocyte mitogenesis in different rat strains exposed to footshock during early diurnal and nocturnal time periods. Psychoneuroendocrinology, 1995, 20, 821-835.	2.7	14
104	Ins and Outs in Environmental and Occupational Safety Studies of Asthma and Engineered Nanomaterials. ACS Nano, 2017, 11, 7565-7571.	14.6	14
105	Abnormal Expression of c-Myc Oncogene in NK Cells in Patients with Cancer. International Journal of Molecular Sciences, 2019, 20, 756.	4.1	14
106	Immune-mediated diseases: where do we stand?. Advances in Experimental Medicine and Biology, 2007, 601, 3-12.	1.6	14
107	Regulation of dendropoiesis in cancer. Clinical Immunology Newsletter, 1999, 19, 135-139.	0.1	13
108	Immunological targets for cancer therapy: new recognition. ImmunoTargets and Therapy, 2018, Volume 7, 83-85.	5.8	13

#	Article	IF	CITATIONS
109	Immune-Mediated Diseases: Where Do We Stand?. Advances in Experimental Medicine and Biology, 2007, , 1-12.	1.6	13
110	Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses. Cancer Immunology Research, 2022, 10, 1141-1154.	3.4	13
111	Recognition of Live Phosphatidylserine-Labeled Tumor Cells by Dendritic Cells: A Novel Approach to Immunotherapy of Skin Cancer. Cancer Research, 2009, 69, 2487-2496.	0.9	12
112	Regulation of Carcinogenesis by Sensory Neurons and Neuromediators. Cancers, 2022, 14, 2333.	3.7	12
113	NK Cells Mediate Flt3 Ligand-Induced Protection of Dendritic Cell Precursors In Vivo from the Inhibition by Prostate Carcinoma in the Murine Bone Marrow Metastasis Model. Journal of Immunotherapy, 2003, 26, 468-472.	2.4	11
114	Regulation of dendritic cell expansion in aged athymic nude mice by FLT3 ligand. Experimental Gerontology, 2004, 39, 339-348.	2.8	11
115	Alterations of oncogenes expression in NK cells in patients with cancer. Immunity, Inflammation and Disease, 2017, 5, 493-502.	2.7	11
116	Characterization of pulmonary responses in mice to asbestos/asbestiform fibers using gene expression profiles. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2018, 81, 60-79.	2.3	11
117	Oncogenes in immune cells as potential therapeutic targets. ImmunoTargets and Therapy, 2018, Volume 7, 21-28.	5.8	11
118	Incidence and Management of Therapeutic Monoclonal Antibody Interference in Monoclonal Gammopathy Monitoring. journal of applied laboratory medicine, The, 2020, 5, 29-40.	1.3	10
119	<p>Assessing Immune Response to SARS-CoV-2 Infection</p> . ImmunoTargets and Therapy, 2020, Volume 9, 111-114.	5.8	10
120	Evaluation of SARS-CoV-2 prototype serologic test in hospitalized patients. Clinical Biochemistry, 2020, 86, 8-14.	1.9	9
121	A Carbon Nanotube Sensor Array for the Label-Free Discrimination of Live and Dead Cells with Machine Learning. Analytical Chemistry, 2022, 94, 3565-3573.	6.5	9
122	A novel approach to remove interference of therapeutic monoclonal antibody with serum protein electrophoresis. Clinical Biochemistry, 2020, 75, 40-47.	1.9	8
123	Racial Differences in S100b Levels in Persons with Schizophrenia. Psychiatric Quarterly, 2020, 91, 137-145.	2.1	8
124	A Cross-Sectional Study of SARS-CoV-2 Seroprevalence between Fall 2020 and February 2021 in Allegheny County, Western Pennsylvania, USA. Pathogens, 2021, 10, 710.	2.8	8
125	Multiplex assessment of SARS-CoV-2 antibodies improves assay sensitivity and correlation with neutralizing antibodies. Clinical Biochemistry, 2021, 97, 54-61.	1.9	8
126	Tumor Innervation: History, Methodologies, and Significance. Cancers, 2022, 14, 1979.	3.7	8

#	Article	IF	CITATIONS
127	Preparation of Human Dendritic Cells for Tumor Vaccination., 2003, 215, 437-462.		8
128	Neuroimmune Regulation of Surgery-Associated Metastases. Cells, 2021, 10, 454.	4.1	7
129	Cerebrospinal Fluid Leak Detection with a Carbon Nanotube-Based Field-Effect Transistor Biosensing Platform. ACS Applied Materials & Samp; Interfaces, 2022, 14, 1684-1691.	8.0	7
130	New perspectives in cancer immunotherapy and immunomonitoring. Future Oncology, 2009, 5, 941-944.	2.4	5
131	Cancer Therapy and Dendritic Cell Immunomodulation. , 2009, , 201-216.		5
132	Th1/Th2 balance in cancer, transplantation and pregnancy. Seminars in Immunopathology, 1999, 21, 339-359.	4.0	5
133	Tumor-induced dendritic cell dysfunction. , 2002, , 112-138.		5
134	Notch signaling defects in NK cells in patients with cancer. Cancer Immunology, Immunotherapy, 2021, 70, 981-988.	4.2	4
135	COVID-19 mRNA Vaccines May Cause False Reactivity in Some Serologic Laboratory Tests, Including Rapid Plasma Reagin Tests. American Journal of Clinical Pathology, 2022, 158, 162-166.	0.7	4
136	Nitrogen-Doped Carbon Nanotube Cups for Cancer Therapy. ACS Applied Nano Materials, 2022, 5, 13685-13696.	5.0	4
137	Resolving Transferrin Isoforms via Agarose Gel Electrophoresis. Laboratory Medicine, 2015, 46, 26-33.	1.2	3
138	Respiratory System, Part Two: Allergy and Asthma. , 2017, , 243-253.		3
139	FLT3-LIGAND INHIBITS TUMOR PROGRESSION IN MURINE MODEL. Journal of Immunotherapy, 1996, 19, 466.	2.4	3
140	Immunobiology of Dendritic Cells in Cancer. , 2008, , 101-130.		2
141	MicroRNAs are invading the tumor microenvironment: Fibroblast microRNAs regulate tumor cell motility and invasiveness. Cell Cycle, 2010, 9, 4430-4430.	2.6	2
142	Conference Scene: Immunotherapy reaches new milestones in cancer eradication. Immunotherapy, 2011, 3, 1131-1137.	2.0	2
143	Cancer and infection: friends or foes?. Future Oncology, 2012, 8, 1061-1064.	2.4	2
144	Conference overview: Cancer Immunotherapy and Immunomonitoring (CITIM): Moving forward. Journal of Immunotoxicology, 2012, 9, 231-235.	1.7	2

#	Article	IF	CITATIONS
145	Differences in Dendritic Cell Activation and Distribution After Intravenous, Intraperitoneal, and Subcutaneous Injection of Lymphoma Cells in Mice. Advances in Experimental Medicine and Biology, 2007, 601, 257-264.	1.6	2
146	Immunobiology of Dendritic Cells in Cancer. , 2014, , 151-184.		2
147	Immunoglobulin Titers and Immunoglobulin Subtypes. , 2005, , 158-171.		1
148	Dendritic Cells in the Tumor Microenvironment. , 2016, , 499-511.		1
149	Role of the Immunological Environment in Cancer Initiation, Development and Progression. , 2013, , 1-12.		1
150	Malfunction of the Dendritic Cell System in Cancer. , 2004, , 49-65.		1
151	Dendritic Cells in Cancer: Emergenceof the Discipline. , 2009, , 11-30.		1
152	Evaluation of the Tumor Immunoenvironment in Clinical Trials. , 2013, , 695-706.		1
153	Infection and Cancer: Multi-directorial Relationship. , 2015, , 1-10.		1
154	Handling Sera and Obtaining Fluid from Different Compartments: Practical Considerations. , 2005, , 121-130.		0
155	Pediatric Hypereosinophilia, Liver Disfunction, and Hemolytic Anemia with Autoimmune Differential. journal of applied laboratory medicine, The, 2020, 5, 1111-1116.	1.3	O
156	New Syphilis Serology Testing Requires New Reporting Algorithms. journal of applied laboratory medicine, The, 2020, 5, 601-604.	1.3	0
157	ChemolmmunoModulation: Focus on Myeloid Regulatory Cells. , 2013, , 603-619.		O
158	Analysis of Myeloid-Derived Suppressor Cells in Patients with Cancer., 2013,, 707-723.		0
159	Comorbid Development of Infection and Cancer. , 2015, , 315-332.		0
160	OUP accepted manuscript. journal of applied laboratory medicine, The, 2022, , .	1.3	0